Uber Technologies, Inc — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Uber Technologies, Inc filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $52.02B | Feb 13, 2026 |
| FY2025 | Dec 31, 2024 | $43.98B | Feb 13, 2026 |
| FY2025 | Dec 31, 2023 | $37.28B | Feb 13, 2026 |
| FY2024 | Dec 31, 2022 | $31.88B | Feb 14, 2025 |
| FY2023 | Dec 31, 2021 | $17.46B | Feb 15, 2024 |
| FY2022 | Dec 31, 2020 | $11.14B | Feb 21, 2023 |
| FY2021 | Dec 31, 2019 | $13.00B | Feb 24, 2022 |
| FY2020 | Dec 31, 2018 | $10.43B | Mar 1, 2021 |
| FY2019 | Dec 31, 2017 | $7.93B | Mar 2, 2020 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $10.05B | Feb 13, 2026 |
| FY2025 | Dec 31, 2024 | $9.86B | Feb 13, 2026 |
| FY2025 | Dec 31, 2023 | $1.89B | Feb 13, 2026 |
| FY2024 | Dec 31, 2022 | ($9.14B) | Feb 14, 2025 |
| FY2023 | Dec 31, 2021 | ($496.00M) | Feb 15, 2024 |
| FY2022 | Dec 31, 2020 | ($6.77B) | Feb 21, 2023 |
| FY2021 | Dec 31, 2019 | ($8.51B) | Feb 24, 2022 |
| FY2020 | Dec 31, 2018 | $997.00M | Mar 1, 2021 |
| FY2019 | Dec 31, 2017 | ($4.03B) | Mar 2, 2020 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $5.57B | Feb 13, 2026 |
| FY2025 | Dec 31, 2024 | $2.80B | Feb 13, 2026 |
| FY2025 | Dec 31, 2023 | $1.11B | Feb 13, 2026 |
| FY2024 | Dec 31, 2022 | ($1.83B) | Feb 14, 2025 |
| FY2023 | Dec 31, 2021 | ($3.83B) | Feb 15, 2024 |
| FY2022 | Dec 31, 2020 | ($4.86B) | Feb 21, 2023 |
| FY2021 | Dec 31, 2019 | ($8.60B) | Feb 24, 2022 |
| FY2020 | Dec 31, 2018 | ($3.03B) | Mar 1, 2021 |
| FY2019 | Dec 31, 2017 | ($4.08B) | Mar 2, 2020 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $3.40B | Feb 13, 2026 |
| FY2025 | Dec 31, 2024 | $3.11B | Feb 13, 2026 |
| FY2025 | Dec 31, 2023 | $3.16B | Feb 13, 2026 |
| FY2024 | Dec 31, 2022 | $2.80B | Feb 14, 2025 |
| FY2023 | Dec 31, 2021 | $2.05B | Feb 15, 2024 |
| FY2022 | Dec 31, 2020 | $2.21B | Feb 21, 2023 |
| FY2021 | Dec 31, 2019 | $4.84B | Feb 24, 2022 |
| FY2020 | Dec 31, 2018 | $1.51B | Mar 1, 2021 |
| FY2019 | Dec 31, 2017 | $1.20B | Mar 2, 2020 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $10.10B | Feb 13, 2026 |
| FY2025 | Dec 31, 2024 | $7.14B | Feb 13, 2026 |
| FY2025 | Dec 31, 2023 | $3.59B | Feb 13, 2026 |
| FY2024 | Dec 31, 2022 | $642.00M | Feb 14, 2025 |
| FY2023 | Dec 31, 2021 | ($445.00M) | Feb 15, 2024 |
| FY2022 | Dec 31, 2020 | ($2.75B) | Feb 21, 2023 |
| FY2021 | Dec 31, 2019 | ($4.32B) | Feb 24, 2022 |
| FY2020 | Dec 31, 2018 | ($1.54B) | Mar 1, 2021 |
| FY2019 | Dec 31, 2017 | ($1.42B) | Mar 2, 2020 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $336.00M | Feb 13, 2026 |
| FY2025 | Dec 31, 2024 | $242.00M | Feb 13, 2026 |
| FY2025 | Dec 31, 2023 | $223.00M | Feb 13, 2026 |
| FY2024 | Dec 31, 2022 | $252.00M | Feb 14, 2025 |
| FY2023 | Dec 31, 2021 | $298.00M | Feb 15, 2024 |
| FY2022 | Dec 31, 2020 | $616.00M | Feb 21, 2023 |
| FY2021 | Dec 31, 2019 | $588.00M | Feb 24, 2022 |
| FY2020 | Dec 31, 2018 | $558.00M | Mar 1, 2021 |
| FY2019 | Dec 31, 2017 | $821.00M | Mar 2, 2020 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $61.80B | Feb 13, 2026 |
| FY2025 | Dec 31, 2024 | $51.24B | Feb 13, 2026 |
| FY2024 | Dec 31, 2023 | $38.70B | Feb 14, 2025 |
| FY2023 | Dec 31, 2022 | $32.11B | Feb 15, 2024 |
| FY2022 | Dec 31, 2021 | $38.77B | Feb 21, 2023 |
| FY2021 | Dec 31, 2020 | $33.25B | Feb 24, 2022 |
| FY2020 | Dec 31, 2019 | $31.76B | Mar 1, 2021 |
| FY2019 | Dec 31, 2018 | $23.99B | Mar 2, 2020 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $33.72B | Feb 13, 2026 |
| FY2025 | Dec 31, 2024 | $28.77B | Feb 13, 2026 |
| FY2024 | Dec 31, 2023 | $26.02B | Feb 14, 2025 |
| FY2023 | Dec 31, 2022 | $23.61B | Feb 15, 2024 |
| FY2022 | Dec 31, 2021 | $23.43B | Feb 21, 2023 |
| FY2021 | Dec 31, 2020 | $19.50B | Feb 24, 2022 |
| FY2020 | Dec 31, 2019 | $16.58B | Mar 1, 2021 |
| FY2019 | Dec 31, 2018 | $17.20B | Mar 2, 2020 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $27.04B | Feb 13, 2026 |
| FY2025 | Dec 31, 2024 | $21.56B | Feb 13, 2026 |
| FY2024 | Dec 31, 2023 | $11.25B | Feb 14, 2025 |
| FY2023 | Dec 31, 2022 | $7.34B | Feb 15, 2024 |
| FY2022 | Dec 31, 2021 | $14.46B | Feb 21, 2023 |
| FY2021 | Dec 31, 2020 | $12.27B | Feb 24, 2022 |
| FY2020 | Dec 31, 2019 | $14.19B | Mar 1, 2021 |
| FY2019 | Dec 31, 2018 | ($7.39B) | Mar 2, 2020 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $8.93B | Feb 13, 2026 |
| FY2025 | Dec 31, 2024 | $8.07B | Feb 13, 2026 |
| FY2025 | Dec 31, 2023 | $8.15B | Feb 13, 2026 |
| FY2024 | Dec 31, 2022 | $8.26B | Feb 14, 2025 |
| FY2023 | Dec 31, 2021 | $8.42B | Feb 15, 2024 |
| FY2022 | Dec 31, 2020 | $6.11B | Feb 21, 2023 |
| FY2021 | Dec 31, 2019 | $167.00M | Feb 24, 2022 |
| FY2020 | Dec 31, 2018 | $153.00M | Mar 1, 2021 |
| FY2019 | Dec 31, 2017 | $39.00M | Mar 2, 2020 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($10.63B) | Feb 13, 2026 |
| FY2025 | Dec 31, 2024 | ($20.73B) | Feb 13, 2026 |
| FY2024 | Dec 31, 2023 | ($30.59B) | Feb 14, 2025 |
| FY2023 | Dec 31, 2022 | ($32.77B) | Feb 15, 2024 |
| FY2022 | Dec 31, 2021 | ($23.63B) | Feb 21, 2023 |
| FY2021 | Dec 31, 2020 | ($23.13B) | Feb 24, 2022 |
| FY2020 | Dec 31, 2019 | ($16.36B) | Mar 1, 2021 |
| FY2019 | Dec 31, 2018 | ($7.87B) | Mar 2, 2020 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $7.11B | Feb 13, 2026 |
| FY2025 | Dec 31, 2024 | $5.89B | Feb 13, 2026 |
| FY2025 | Dec 31, 2023 | $4.68B | Feb 13, 2026 |
| FY2024 | Dec 31, 2022 | $4.21B | Feb 14, 2025 |
| FY2023 | Dec 31, 2021 | $4.30B | Feb 15, 2024 |
| FY2022 | Dec 31, 2020 | $5.65B | Feb 21, 2023 |
| FY2021 | Dec 31, 2019 | $10.87B | Feb 24, 2022 |
| FY2020 | Dec 31, 2018 | $6.41B | Mar 1, 2021 |
| FY2019 | Dec 31, 2017 | $4.39B | Mar 2, 2020 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $10.60B | Feb 13, 2026 |
| FY2024 | Dec 31, 2024 | $9.58B | Feb 14, 2025 |
| FY2023 | Dec 31, 2023 | $9.56B | Feb 15, 2024 |
| FY2022 | Dec 31, 2022 | $9.36B | Feb 21, 2023 |
| FY2021 | Dec 31, 2021 | $9.39B | Feb 24, 2022 |
| FY2020 | Dec 31, 2020 | $7.91B | Mar 1, 2021 |
| FY2019 | Dec 31, 2019 | $5.79B | Mar 2, 2020 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 4 | Feb 13, 2026 |
| FY2025 | Dec 31, 2024 | 4 | Feb 13, 2026 |
| FY2025 | Dec 31, 2023 | 0 | Feb 13, 2026 |
| FY2024 | Dec 31, 2022 | (4) | Feb 14, 2025 |
| FY2023 | Dec 31, 2021 | 0 | Feb 15, 2024 |
| FY2022 | Dec 31, 2020 | (3) | Feb 21, 2023 |
| FY2021 | Dec 31, 2019 | (6) | Feb 24, 2022 |
| FY2020 | Dec 31, 2018 | 0 | Mar 1, 2021 |
| FY2019 | Dec 31, 2017 | (9) | Mar 2, 2020 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 4 | Feb 13, 2026 |
| FY2025 | Dec 31, 2024 | 4 | Feb 13, 2026 |
| FY2025 | Dec 31, 2023 | 0 | Feb 13, 2026 |
| FY2024 | Dec 31, 2022 | (4) | Feb 14, 2025 |
| FY2023 | Dec 31, 2021 | 0 | Feb 15, 2024 |
| FY2022 | Dec 31, 2020 | (3) | Feb 21, 2023 |
| FY2021 | Dec 31, 2019 | (6) | Feb 24, 2022 |
| FY2020 | Dec 31, 2018 | 0 | Mar 1, 2021 |
| FY2019 | Dec 31, 2017 | (9) | Mar 2, 2020 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 2.07B | Feb 13, 2026 |
| FY2025 | Dec 31, 2024 | 2.11B | Feb 13, 2026 |
| FY2024 | Dec 31, 2023 | 2.07B | Feb 14, 2025 |
| FY2023 | Dec 31, 2022 | 2.01B | Feb 15, 2024 |
| FY2022 | Dec 31, 2021 | 1.95B | Feb 21, 2023 |
| FY2021 | Dec 31, 2020 | 1.85B | Feb 24, 2022 |
| FY2020 | Dec 31, 2019 | 1.72B | Mar 1, 2021 |
| FY2019 | Dec 31, 2018 | 457.19M | Mar 2, 2020 |